1 d histopathological findings consistent with drug eruption.

2 treatment outcomes of patients with purpuric drug eruptions.

3 r reflect the dermatologic classification of drug eruptions.

4 d to mild, uncomplicated exanthems and fixed drug eruptions.

5  been previously reported to cause lichenoid drug eruptions.

6 nisms underlying pegylated IFN-alpha-induced drug eruptions.

7 001-related serious adverse events (atypical drug eruption and thrombocytopenia) and two in the tenof

8 tis, varicella zoster virus infection, fixed drug eruption, and IgA pemphigus.

9 lpha in the pathogenesis of psoriasis, fixed drug eruption, atopic and allergic contact dermatitis.

10                                     Purpuric drug eruptions caused by epidermal growth factor recepto

11 lly thought to be associated with eczematous drug eruptions (ie, eczematous and interface dermatitis)

12          Hepatitis C patients suffering from drug eruptions in association with administration of peg

13 eatening drug reaction, developed a systemic drug eruption, or had to prematurely stop triple therapy

14                                         Like drug eruptions, viral exanthema, and toxic erythema of c

15 ; 12 female and 2 male) and 18 with purpuric drug eruptions with pustules (mean [SD] age, 64 [11] yea

16        Thirty-two patients, 14 with purpuric drug eruptions without pustules (mean [SD] age, 60 [11]